Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Perspective
Postacute sequelae of SARS-CoV-2 infection. Osteonecrosis must not be overlooked
Antonios A. Koutalos*, Nikolaos Stefanou, Konstantinos N. Malizos
Department of Orthopaedic Surgery & Musculoskeletal Trauma, Faculty of Medicine, University of Thessaly, Larissa, Greece

ABSTRACT
Recovery from COVID-19 is not always uneventful, especially in critically ill hospitalized patients. Persistent symptoms including fatigue/weakness, shortness of breath, anxiety, and depression have been described at one-year follow-up. Furthermore, symptoms from the musculoskeletal system like joint pain or stiffness are underreported in studies with long-term follow-up of up to one year. Infection with SARS-CoV-2 itself has been associated with endothelial damage, and together with high-dose corticosteroid treatment, it is predisposed to the dissemination of microthrombi and the development of femoral head osteonecrosis (FHO), as it has been shown during the previous (2003–2004) coronavirus outbreaks. A resurgence of FHO cases is anticipated but this is not reflected in the existing studies with long-term follow-up. Prompt diagnosis is critical for early treatment and possibly for the hip joint preservation. Patients with COVID-19 treated with corticosteroids should be screened for avascular necrosis early after discharge from the hospital. Every healthcare worker involved in the management of these patients should maintain a high level of suspicion and should be alert when patients report symptoms such as vague aches at the buttocks, hip area, adductors, and/or above the knee. Studies are needed to identify risk factors for FHO including disease severity, type of steroid, cumulative dose, and duration of treatment.

© 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

The immense burden of the COVID-19 pandemic has globally challenged the healthcare delivery and the healthcare system reserves. It is important that the postacute sequelae of SARS-CoV-2 infection (PASC) and complications of the disease and the therapeutic interventions in millions of patients worldwide are intensively studied and monitored.

Few studies have reported PASC after infection with SARS-CoV-2. Darcis et al (2021) reported improvement in radiographic imaging and pulmonary functional tests but persistence of symptoms after six months. The most prevalent symptoms were shortness of breath and fatigue. Fatigue and memory impairment were unexpectedly increased over time. There was a trend for association between diffusion capacity of carbon monoxide and persistent symptoms. In another study, Huang et al reported a wide range of lesser known PASC in COVID-19 survivors one year after discharge from the hospital (Huang et al., 2021). Again, dyspnea, anxiety, and depression increased in prevalence at one year. Female sex and corticosteroid therapy at the acute phase were risk factors for fatigue or muscle weakness, with more prevalent mobility or discomfort problems than in the matched controls (Huang et al., 2021).

Reporting PASC regarding the musculoskeletal system, however, is inconsistent and variable. Fatigue and muscle weakness are some of the most common persistent long-term symptoms and are probably associated with lung diffusion capacity injury, viral myositis, or steroids myopathy (Huang et al., 2021; Tsai et al., 2004). Other symptoms such as mobility and discomfort problems, joint pain, and stiffness are not systematically investigated and reported. Huang et al reported a 12% incidence of joint pain and 4% of myalgia. In addition, 9% of the patients had mobility problems (Huang et al., 2021). Generally, the impact of SARS-CoV-2 infection and the combined therapeutic interventions on the skeletal system have not been thoroughly investigated as part of the follow-up protocol in most long-term studies. More specifically, there is no report of the incidence of femoral head osteonecrosis (FHO) or other necrotic lesions of the skeleton.

* Corresponding author: Antonios A. Koutalos, Department of Orthopaedic Surgery & Musculoskeletal Trauma, Faculty of Medicine, University of Thessaly, 3 University Str. 41110, Larissa, Greece, Tel.: +302413502719, Fax: +30241350101.
E-mail address: akoutalos@gmail.com (A.A. Koutalos).
* Address: Department of Orthopaedic Surgery & Musculoskeletal Trauma, Faculty of Medicine, University of Thessaly, 3 University Str. 41500, Biopolis, Larissa, Greece.

https://doi.org/10.1016/j.ijid.2022.04.026
1201-9712/© 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
of 2000 mg of prednisolone or equivalent is associated with increased risk of FHOn (Jones, 2001). This varies with daily administered dose, type of steroid, maximum dose, and underlying disease (Powell et al., 2010). The minimum dose for FHOn development is approximately 700 mg of prednisolone or equivalent (Anderton and Helm, 1982). A duration of at least six months to one year is needed after corticosteroid treatment before FHOn development symptoms (McKee et al., 2001). Corticosteroids may induce osteonecrosis (ON), mainly through altering the lipid metabolism resulting in fat accumulation in the bone marrow and enlargement of fat cells with subsequently increased intramedullary pressure. Furthermore, by decreasing the blood supply at the femoral head through fat embolism and microthrombosis and by corticosteroid-induced apoptosis of the osteocytes, corticosteroids may cause ON (Wang et al., 2018).

In the case of COVID-19, the “thrombo-inflammatory cascade” causes endothelial injury and predisposes to microthrombosis. The hypercoagulability state of SARS-CoV-2 infection is also considered a risk factor for ON (Mehta et al., 2020). In addition, other treatments studied during the early phase of the pandemic such as the antivirals ritonavir and lopinavir may trigger FHOn (Patel et al., 2021).

Observational studies of patients treated with corticosteroids for SARS-1 epidemic in 2003 reported FHOn and/or major joints, as early as four months from the infection, ranging from 24–41%, when the patients were followed up to three and even to seven years (Guo et al., 2014; Hong and Du, 2004; Hui et al., 2009; Zhao et al., 2010; Zhao et al., 2013). FHOn was confirmed by MRI, which is considered the method of choice for early-stage diagnosis. The mean total steroid dose varied from 4904–4117 mg of prednisone or equivalent, and higher doses were associated with increased risk for ON (Guo et al., 2014). In some cases, bilateral FHOn was noted. Besides femoral head, other sites were also affected, including the shoulder, knee, and ankle (Guo et al., 2014; Hong and Du, 2004; Hui et al., 2009; Zhao et al., 2010; Zhao et al., 2013). The natural history of these necrotic bone lesions at the weight bearing areas of the joints involves the progression to articular surface collapse, painful and restricted range of motion, and nonreversible joint destruction (Zhao et al., 2010; Zhao et al., 2013). In a recent review, it was reported that the time interval between corticosteroid treatment and FHOn onset was shorter in patients with COVID-19 than those without COVID-19, and in some cases, FHOn develops without corticosteroid treatment (Shetty, 2021). The precise cumulative corticosteroids dose and/or duration of therapy for developing FHOn cannot be estimated in SARS-CoV-2 infection, but higher dose, longer duration, severe COVID-19 pneumonia, intensive care unit admission, elevated inflammatory serum markers, and personal history of smoking or excessive alcohol consumption have been postulated as potential risk factors (Shetty, 2021). However, no observational cohort study has been published regarding COVID-19 and FHOn incidence.
When assessing PASC, especially in patients treated with a high dose of corticosteroids, it is crucial to maintain a high index of suspicion for the development of the initially asymptomatic (which could last for several months but potentially evolving to collapse) infarcts at the femoral head, knees, shoulders, and/or talus (Krez et al., 2021; Zhang et al., 2021; Zhao et al., 2010). Close follow-up with MRI screening of the hips and all major joints should be conducted in the first 3–4 months after discharge for early detection of the lesions, before the collapse of the necrotic bone. Upon diagnosis, prompt intervention might save the native joint and avoid an undesirable total joint replacement in young patients. All specialties involved in management of patients with COVID-19 should be aware of this potential serious consequence of the disease and its treatment. In addition, mobility problems caused by fatigue or muscle weakness should be promptly managed to avoid any decline in quality of life of patients with COVID-19.

Furthermore, future studies of long-term follow-up of patients with SARS-CoV-2 infection should include in their methodology the reporting of musculoskeletal symptoms and especially, the incidence of FHOn. In addition, these studies could help determine the predisposing factors that are associated with FHOn development, including the cumulative dose of corticosteroids, type and route of corticosteroid administration, duration of therapy, disease severity, inflammatory biomarkers, and other yet unknown risk factors.

Ethical Approval

The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the University General Hospital of Larissa.

Declaration of Competing Interest

The authors have no competing interests to declare.

Acknowledgments

No funds were received for this perspective article.

References

Agarwala SR, Vijayvargiya M, Pandey P. Avascular necrosis as a part of “long COVID-19. BMJ Case Rep 2021;14.

Anderton JM, Helm R. Multiple joint osteonecrosis following short-term steroid therapy. Case report. J Bone Joint Surg Am 1982;64:139–41.

Darci G, Bouquegneau A, Maes N, Thys M, Henket M, Labye F, et al. Long-term clinical follow-up of patients suffering from moderate-to-severe COVID-19 infection: a monocentric prospective observational cohort study. Int J Infect Dis 2021;109:209–16 doi:

Guo KJ, Zhao FC, Guo Y, Li FL, Zhu L, Zheng W. The influence of age, gender and treatment with steroids on the incidence of osteonecrosis of the femoral head during the management of severe acute respiratory syndrome: a retrospective study. Bone Joint J 2014 96-B:259–62.

Hong N, Du XK. Avascular necrosis of bone in severe acute respiratory syndrome. Clin Radiol 2004;59:602–8.

Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet 2021;398:747–58.

Hui L, de Vlas SJ, Liu W, et al. Avascular osteonecrosis after treatment of SARS: a 3-year longitudinal study 2009;14(Suppl. 1):79–84.

Jones JP. Osteonecrosis. In: Koopman WJ, editor. Arthritis and allied conditions: a textbook of rheumatology. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 2143–64 p.

Krez A, Laine J, Heilbronner A, Park-Min KH, Kaneko K, Pannellini T, et al. Risk factors for multi-joint disease in patients with glucocorticoid-induced osteonecrosis. Osteoporos Int 2021;32:2095–103.

McKee MD, Waddell JP, Kudo PA, Schemitsch EH, Richards RR. Osteonecrosis of the femoral head in men following short-course corticosteroid therapy: a report of 15 cases. CMAJ 2001;164:205–6.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033–4.

Mont MA, Pivce R, Banerjee S, Isba K, Elmaleh RK, Jones LC. High-dose corticosteroid use and risk of hip osteonecrosis: meta-analysis and systematic literature review. J Arthroplasty 2015;30:1506–1512.e5

Patel TK, Patel PR, Barvaliya M, Saurabh MK, Bhalla HL, Khosla PP. Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials. J Infect Public Health 2021;14:740–8.

Powell C, Chang C, Naguna SM, Cheema G, Gerishwina ME. Steroid induced osteonecrosis: an analysis of steroid dosing risk. Autoinmun Rev 2010;9:721–43.

Shetty GM. Double trouble-COVID-19 and the widespread use of corticosteroids: are we staring at an osteonecrosis epidemic? Indian J Orthop 2021;55:1–11 doi:

Tsai LC, Hsieh ST, Chao CC, Chen YC, Lin YH, Chang SC, et al. Neuromuscular disorders in severe acute respiratory syndrome. Arch Neurol 2004;61:1669–73.

Wang A, Ren M, Wang J. The pathogenesis of steroid-induced osteonecrosis of the femoral head: A systematic review of the literature. Gene 2018;671:103–9.

Zhang S, Wang C, Shi L, Yue Q. Beware of steroid-induced avascular necrosis of the femoral head in the treatment of COVID-19: Experience and lessons from the SARS epidemic. Drug Des Devel Ther 2021;15:983–95.

Zhao FC, Guo KJ, Li ZR. Osteonecrosis of the femoral head in SARS patients: seven years later. Eur J Orthop Surg Traumatol 2013;23:671–7.

Zhao FC, Li ZR, Zhang NF, Wang BL, Sun W, Cheng LM, et al. Lesion size changes in osteonecrosis of the femoral head: a long-term prospective study using MRI. Int Orthop 2010;34:799–804.

Zhao Y, Yang C, Ao X, Xiong Y, Shang Y, He J, et al. Follow-up study on the COVID-19 survivors after one year discharged from hospital. Int J Infect Dis 2021;112:173–82.